2. Search Result
Search Result
Results for "

SARS-CoV-2 3CLpro inhibitor

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

3

Natural
Products

2

Isotope-Labeled Compounds

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146998
    SARS-CoV-2 3CLpro-IN-2

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .
    SARS-CoV-2 3CLpro-IN-2
  • HY-W760546
    SARS-CoV-2 3CLpro-IN-15

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .
    SARS-CoV-2 3CLpro-IN-15
  • HY-N12384
    (25S)-Antcin B

    		SARS-CoV Infection
    Antcin-B is a potent inhibitor of 3CLPro with high affinity. Antcin-B can be used in study SARS-CoV-2 .
    (25S)-Antcin B
  • HY-162674
    MERS-CoV-IN-2

    		SARS-CoV Infection
    MERS-CoV-IN-2 (compound 3c) is a MERS-CoV 3CLpro inhibitor (IC50=17nM). MERS-CoV-IN-2 inhibits the activity of the 3CLpro enzyme by binding to the active site of the enzyme, specifically the S4 subsite, thereby exhibiting antiviral activity against SARS-CoV-2 and MERS-CoV .
    MERS-CoV-IN-2
  • HY-155979
    SARS-CoV-2 3CLpro-IN-16

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro .
    SARS-CoV-2 3CLpro-IN-16
  • HY-170357
    SARS-CoV-2 3CLpro-IN-28

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-28 (Compound 19) is an inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.018 μM .
    SARS-CoV-2 3CLpro-IN-28
  • HY-147804
    SARS-CoV-2 3CLpro-IN-3

    		SARS-CoV Bacterial Fungal Infection
    SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .
    SARS-CoV-2 3CLpro-IN-3
  • HY-155981
    SARS-CoV-2 3CLpro-IN-18

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.478 μM). SARS-CoV-2 3CLpro-IN-18 inhibits SARS-CoV-2 in Vero E6 cells (EC50= 2.499 μM) with low cytotoxicity (CC50 > 200 μM) .
    SARS-CoV-2 3CLpro-IN-18
  • HY-155980
    SARS-CoV-2 3CLpro-IN-17

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC50s: 0.322 μM) .
    SARS-CoV-2 3CLpro-IN-17
  • HY-155540
    SARS-CoV-2 3CLpro-IN-14

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active SARS-CoV-2 3CLpro inhibitor. SARS-CoV-2 3CLpro-IN-14 shows significant anti-SARS-CoV-2 activity (EC50 = 0.18 μM) and low cytotoxicity (CC50 > 50 μM) in Vero E6 cells .
    SARS-CoV-2 3CLpro-IN-14
  • HY-152005
    SARS-CoV-2 3CLpro-IN-6

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL pro with an IC50 value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 3CLpro-IN-6
  • HY-147805
    SARS-CoV-2 3CLpro-IN-4

    		SARS-CoV Bacterial Fungal Infection
    SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .
    SARS-CoV-2 3CLpro-IN-4
  • HY-149264
    SARS-CoV-2 3CLpro-IN-13

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-13 is a potent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity .
    SARS-CoV-2 3CLpro-IN-13
  • HY-157477
    SARS-CoV-2 3CLpro-IN-22

    		SARS-CoV Cathepsin Infection
    SARS-CoV-2 3CLpro-IN-22 (Compound 17) is a cathepsin L (CTSL ) inhibitor with an IC50 value of 32.5 nM. SARS-CoV-2 3CLpro-IN-22 can be used for the study of SARS-CoV-2 virus .
    SARS-CoV-2 3CLpro-IN-22
  • HY-161919
    SARS-CoV-2 3CLpro-IN-25

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-25 (compound 56) inhibits the SARS-CoV-2 3CLpro with the IC50 of 70 nM and displays antiviral activity in cells with the EC50 of 3.1 μM .
    SARS-CoV-2 3CLpro-IN-25
  • HY-151535
    SARS-CoV-2 3CLpro-IN-5

    		SARS-CoV Infection Inflammation/Immunology
    SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CL pro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL pro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 3CLpro-IN-5
  • HY-155187
    SARS-CoV-2 3CLpro-IN-20

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM, Ki: ?0.33?μM) .
    SARS-CoV-2 3CLpro-IN-20
  • HY-168152
    SARS-CoV-2 3CLpro-IN-26

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is an allosteric inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.43 μM. SARS-CoV-2 3CLpro-IN-26 exhibits good cell permeability and is able to effectively cross the cell membrane, after co-incubation with Vero-E6 cells .
    SARS-CoV-2 3CLpro-IN-26
  • HY-168564
    SARS-CoV-2 3CLpro-IN-27

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-27 (Compound 9H) is an inhibitor of SARS-CoV-2 3CL pro with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-27 exhibits excellent anti-SARS-CoV-2 replicon activity, demonstrating an EC50 value of 5 nM .
    SARS-CoV-2 3CLpro-IN-27
  • HY-155186
    SARS-CoV-2 3CLpro-IN-19

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC50s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC50 values between 30-69 nM .
    SARS-CoV-2 3CLpro-IN-19
  • HY-169410
    SARS-CoV-2 3CLpro-IN-29

    		SARS-CoV Virus Protease Infection
    3CLPro-IN-3 (Compound A36) is an inhibitor for SARS-CoV-2 3CLpro with IC50 of 51.3 nM. 3CLPro-IN-3 exhibits antiviral activity against human coronavirus 229E, OC43 and mouse hepatitis virus MHV .
    SARS-CoV-2 3CLpro-IN-29
  • HY-156007
    SARS-CoV-2 3CLpro-IN-21

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CL pro with an IC50 of 0.03 μM. SARS-CoV-2 3CLpro-IN-21 also inhibits SARS-CoV-13CL pro with an IC50 of 0.12μM .
    SARS-CoV-2 3CLpro-IN-21
  • HY-144833
    SARS-CoV-2 3CLpro-IN-1

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL pro. 3CL pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .
    SARS-CoV-2 3CLpro-IN-1
  • HY-132886
    SARS-CoV-2-IN-6

    		SARS-CoV Infection
    SARS-CoV-2-IN-6 is a SARS-CoV-2 3CLpro inhibitor that shows the most potent enzyme inhibitory IC50 value of 73 nM.
    SARS-CoV-2-IN-6
  • HY-162236
    SARS-CoV-2-IN-80

    		SARS-CoV Infection
    SARS-CoV-2-IN-80 (compound 13) is a potent SARS-CoV-2 3CLpro inhibitor with an IC50 value of 0.964 µM .
    SARS-CoV-2-IN-80
  • HY-145276
    SARS-CoV-2-IN-10

    		SARS-CoV Infection
    SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-10
  • HY-145277
    SARS-CoV-2-IN-11

    		SARS-CoV Infection
    SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    SARS-CoV-2-IN-11
  • HY-152009
    SARS-CoV-2 3CLpro-IN-7

    		SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 1.4 µM .
    SARS-CoV-2 3CLpro-IN-7
  • HY-138078
    Lufotrelvir
    1 Publications Verification

    PF-07304814

    		 SARS-CoV Infection
    Lufotrelvir (PF-07304814), a phosphate proagent of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle.
    Lufotrelvir
  • HY-144747
    Hydroxyethylamine

    		SARS-CoV Infection
    Hydroxyethylamine (Compd VII) is a SARS-CoV-2 3CLpro inhibitor with an IC50 of ~10 μM in the spread assay. Hydroxyethylamine has potent antiviral activities .
    Hydroxyethylamine
  • HY-163912
    JZD-07

    		SARS-CoV Infection
    JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of SARS-CoV-2 infection .
    JZD-07
  • HY-144260
    3CPLro-IN-1

    		SARS-CoV Infection
    3CPLro-IN-1 (compound A17) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC50 of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .
    3CPLro-IN-1
  • HY-144263
    3CPLro-IN-2

    		SARS-CoV Infection
    3CPLro-IN-2 (compound C1) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC50 and Ki of 1.55 and 6.09 μM, respectively. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .
    3CPLro-IN-2
  • HY-169974
    SARS-CoV-2-IN-107

    		SARS-CoV Virus Protease NO Synthase Infection Inflammation/Immunology
    SARS-CoV-2-IN-107 (Compound A7) is the inhibitor for SARS-CoV-2 3CLpro with an IC50 of 261.3 nM. SARS-CoV-2-IN-107 inhibits the SARS-CoV-2 replication with an EC50 of 11.7 μM. SARS-CoV-2-IN-107 exhibits anti-inflammatory activity with a NO inhibition rate of 68.6% in LPS (HY-D1056)-stimulated RAW264.7 macrophages .
    SARS-CoV-2-IN-107
  • HY-N8306
    Isojacareubin

    		Bacterial PKC Apoptosis SARS-CoV Cancer
    Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis .
    Isojacareubin
  • HY-136606
    SARS-CoV MPro-IN-1

    		SARS-CoV Infection
    SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC50 of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .
    SARS-CoV MPro-IN-1
  • HY-B0961
    Merbromin

    Mercury dibromofluorescein disodium salt; ZP1

    		 Flavivirus Proteasome Others
    Merbromin is a mixed inhibitor of the 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2, with an IC50 of 2.7 μM. Merbromin effectively inhibits the replication of the Zika virus (ZIKV) and shows anti-ZIKV activity by inhibiting ZIKVpro. Merbromin can also be used as a topical disinfectant for cuts and scrapes, and it serves as a biological dye .
    Merbromin
  • HY-10237S
    Boceprevir-d9

    EBP 520-d9; SCH 503034-d9

    		 Isotope-Labeled Compounds HCV Protease HCV SARS-CoV Infection
    Boceprevir-d9 is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].
    Boceprevir-d9
  • HY-10235S
    Telaprevir-d4

    VX-950-d4

    		 Isotope-Labeled Compounds HCV Protease HCV SARS-CoV Infection
    Telaprevir-d4 is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].
    Telaprevir-d4
  • HY-N0063R
    Punicalagin (Standard)

    		SARS-CoV HBV Infection Metabolic Disease Cancer
    Punicalagin (Standard) is the analytical standard of Punicalagin. This product is intended for research and analytical applications. Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CLpro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 .
    Punicalagin (Standard)
  • HY-10235R
    Telaprevir (Standard)

    		HCV Protease HCV SARS-CoV Infection
    Telaprevir (Standard) is the analytical standard of Telaprevir. This product is intended for research and analytical applications. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .
    Telaprevir (Standard)
  • HY-D0837R
    Imidazole (Standard)

    		Ser/Thr Protease Thrombopoietin Receptor Neurological Disease Inflammation/Immunology
    Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .
    Imidazole (Standard)
  • HY-111074
    DB12055

    MK-0767 analog

    		 SARS-CoV Infection Metabolic Disease
    DB12055 (MK-0767 analog) is a covalent SARS-CoV-2 3CL protease inhibitor. DB12055 has the potential for the study of dyslipidemia and diabetes mellitus .
    DB12055

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: